XENE - Company ID 0001582313
Xenon Pharmaceuticals Inc. (XENE) reported net income of -$345.91M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$345.91M | -47.6% |
| FY 2024 | -$234.33M | -28.5% |
| FY 2023 | -$182.39M | -45.5% |
| FY 2022 | -$125.37M | -58.9% |
| FY 2021 | -$78.88M | -173.5% |
| FY 2020 | -$28.84M | +30.7% |
| FY 2019 | -$41.59M | -20.6% |
| FY 2018 | -$34.50M | -12.4% |
| FY 2017 |
Xenon Pharmaceuticals Inc. (XENE) reported net income of -$345.91M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2012 and fiscal 2025, Xenon Pharmaceuticals Inc.'s net income declined from -$4.30M to -$345.91M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$30.70M |
| -33.5% |
| FY 2016 | -$23.00M | -46.0% |
| FY 2015 | -$15.75M | -221.0% |
| FY 2014 | $13.02M | +8.2% |
| FY 2013 | $12.03M | +379.7% |
| FY 2012 | -$4.30M | - |